MANBIR KAUR: Open Payments
NPI 1437814431 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$263 in 13 payments from 7 companies in 2025. Trend: 2023 $0 · 2024 $148 · 2025 $263
Food & beverage: $263
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 3 | $79 |
| Supernus Pharmaceuticals, Inc. | 4 | $62 |
| ABBVIE INC. | 2 | $39 |
| Alkermes, Inc. | 1 | $27 |
| Bausch Health US, LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
Products named: Auvelity, Qelbree, VRAYLAR, ARISTADA, APLENZIN, AUSTEDO XR, HETLIOZ.
Industry payments across CA — which companies pay providers there.
